JAY ALAN NADEL
Medical Practice in San Francisco, CA
License number
Pennsylvania MD024282L
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
2
San Francisco, CA 94115
Pennsylvania
Pennsylvania
Personal information
See more information about JAY ALAN NADEL at radaris.comName
Address
Phone
2373 Pacific Ave, San Francisco, CA 94115
2371 Pacific Ave, San Francisco, CA 94115
2373 Pacific Ave, San Francisco, CA 94115
Professional information
Jay Nadel, San Francisco CA
Work:
UCSF Medical Center / Moffitt-Long Hospitals
521 Parnassus Ave, San Francisco, CA 94143
521 Parnassus Ave, San Francisco, CA 94143
Dr. Jay Nadel, San Francisco CA - MD (Doctor of Medicine)
Specialties:
Pulmonology
Address:
505 Parnassus Ave SUITE 130, San Francisco 94143
(415) 476-1105 (Phone), (415) 476-2283 (Fax)
UCSF MEDICAL GROUP
505 Parnassus Ave SUITE M1325, San Francisco 94143
(415) 476-1105 (Phone), (415) 502-4186 (Fax)
(415) 476-1105 (Phone), (415) 476-2283 (Fax)
UCSF MEDICAL GROUP
505 Parnassus Ave SUITE M1325, San Francisco 94143
(415) 476-1105 (Phone), (415) 502-4186 (Fax)
Languages:
English
Hospitals:
505 Parnassus Ave SUITE 130, San Francisco 94143
UCSF MEDICAL GROUP
505 Parnassus Ave SUITE M1325, San Francisco 94143
UCSF Medical Center
505 Parnassus Ave, San Francisco 94143
UCSF Medical Center at Mount Zion
1600 Divisadero St, San Francisco 94115
UCSF MEDICAL GROUP
505 Parnassus Ave SUITE M1325, San Francisco 94143
UCSF Medical Center
505 Parnassus Ave, San Francisco 94143
UCSF Medical Center at Mount Zion
1600 Divisadero St, San Francisco 94115
Education:
Medical School
Thomas Jefferson University
Graduated: 1953
Thomas Jefferson University
Graduated: 1953
Preventing Airway Mucus Production By Administration Of Egf-R Antagonists
US Patent:
6551989, Apr 22, 2003
Filed:
May 24, 2001
Appl. No.:
09/865239
Inventors:
Jay A. Nadel - San Francisco CA
Kiyoshi Takeyama - San Francisco CA
Kiyoshi Takeyama - San Francisco CA
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A01N 6100
US Classification:
514 1, 424 113, 424452, 514 4, 514 2
Abstract:
Hypersecretion of mucus in the lungs is inhibited by the administration of an epidermal growth factor receptor (EGF-R) antagonist. The EGF-R antagonist may be in the form of a small organic molecule, an antibody, or portion of an antibody that binds to and blocks the EGF receptor. The EGF-R antagonist is preferably administered by injection in an amount sufficient to inhibit formation of goblet cells in pulmonary airways. The degranulation of goblet cells that results in airway mucus production is thereby inhibited. Assays for screening candidate agents that inhibit goblet cell proliferation are also provided.
Jay A Nadel, San Francisco CA
Specialties:
Pulmonologist
Address:
400 Parnassus Ave, San Francisco, CA 94143
505 Parnassus Ave, San Francisco, CA 94143
505 Parnassus Ave, San Francisco, CA 94143
Preventing Airway Mucus Production By Administration Of Egf-R Antagonists
US Patent:
7358222, Apr 15, 2008
Filed:
Feb 7, 2003
Appl. No.:
10/359932
Inventors:
Jay A. Nadel - San Francisco CA, US
Kiyoshi Takeyama - Tokyo, JP
Kiyoshi Takeyama - Tokyo, JP
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A01N 61/00, A01N 37/16
US Classification:
514 1, 514 2, 514 4, 424 113, 424452
Abstract:
Hypersecretion of mucus in the lungs is inhibited by the administration of an epidermal growth factor receptor (EGF-R) antagonist. The EGF-R antagonist may be in the form of a small organic molecule, an antibody, or portion of an antibody that binds to and blocks the EGF receptor. The EGF-R antagonist is preferably administered by injection in an amount sufficient to inhibit formation of goblet cells in pulmonary airways. The degranulation of goblet cells that results in airway mucus production is thereby inhibited. Assays for screening candidate agents that inhibit goblet cell proliferation are also provided.
Preventing Airway Mucus Production By Administration Of Egf-R Antagonists
US Patent:
7700547, Apr 20, 2010
Filed:
Jan 11, 2008
Appl. No.:
12/013013
Inventors:
Jay A. Nadel - San Francisco CA, US
Kiyoshi Takeyama - San Francisco CA, US
Kiyoshi Takeyama - San Francisco CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A01N 37/15, A01N 61/00, C07K 16/00
US Classification:
514 2, 514 1, 5303871, 5303881, 53038815, 53038822
Abstract:
Hypersecretion of mucus in the lungs is inhibited by the administration of an epidermal growth factor receptor (EGF-R) antagonist. The EGF-R antagonist may be in the form of a small organic molecule, an antibody, or portion of an antibody that binds to and blocks the EGF receptor. The EGF-R antagonist is preferably administered by injection in an amount sufficient to inhibit formation of goblet cells in pulmonary airways. The degranulation of goblet cells that results in airway mucus production is thereby inhibited. Assays for screening candidate agents that inhibit goblet cell proliferation are also provided.
Preventing Airway Mucus Production By Administration Of Egf-R Antagonists
US Patent:
7354894, Apr 8, 2008
Filed:
Mar 31, 2004
Appl. No.:
10/816159
Inventors:
Jay A. Nadel - San Francisco CA, US
Kiyoshi Takeyama - Tokyo, JP
Kiyoshi Takeyama - Tokyo, JP
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A01N 61/00, A01N 43/04, C12N 5/00, A61K 49/00, G01N 33/53
US Classification:
514 1, 435 6, 435 72, 435377, 424 91, 424 92, 514 44, 536 231
Abstract:
Hypersecretion of mucus in the lungs is inhibited by the administration of an epidermal growth factor receptor (EGF-R) antagonist. The EGF-R antagonist may be in the form of a small organic molecule, an antibody, or portion of an antibody that binds to and blocks the EGF receptor. The EGF-R antagonist is preferably administered by injection in an amount sufficient to inhibit formation of goblet cells in pulmonary airways. The degranulation of goblet cells that results in airway mucus production is thereby inhibited. Assays for screening candidate agents that inhibit goblet cell proliferation are also provided.
Preventing Airway Mucus Production By Administration Of Egf-R Antagonists
US Patent:
8048844, Nov 1, 2011
Filed:
Feb 7, 2003
Appl. No.:
10/359982
Inventors:
Jay A. Nadel - San Francisco CA, US
Kiyoshi Takeyama - Tokyo, JP
Kiyoshi Takeyama - Tokyo, JP
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A01N 61/00, A61K 51/00
US Classification:
514 1, 514 2, 514 4, 424 113, 424 9
Abstract:
Hypersecretion of mucus in the lungs is inhibited by the administration of an epidermal growth factor receptor (EGF-R) antagonist. The EGF-R antagonist may be in the form of a small organic molecule, an antibody, or portion of an antibody that binds to and blocks the EGF receptor. The EGF-R antagonist is preferably administered by injection in an amount sufficient to inhibit formation of goblet cells in pulmonary airways. The degranulation of goblet cells that results in airway mucus production is thereby inhibited. Assays for screening candidate agents that inhibit goblet cell proliferation are also provided.
Preventing Airway Mucus Production By Administration Of Egf-R Antagonists
US Patent:
6846799, Jan 25, 2005
Filed:
Jul 14, 2000
Appl. No.:
09/616223
Inventors:
Jay A. Nadel - San Francisco CA, US
Kiyoshi Takeyama - San Francisco CA, US
Kiyoshi Takeyama - San Francisco CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A01N 6100, A01N 4304, G01N 3353, C12N 500, A61K 4900
US Classification:
514 1, 435 6, 435 72, 435377, 536 231, 424 91, 514 44
Abstract:
Hypersecretion of mucus in the lungs is inhibited by the administration of an epidermal growth factor receptor (EGF-R) antagonist. The EGF-R antagonist may be in the form of a small organic molecule, an antibody, or portion of an antibody that binds to and blocks the EGF receptor. The EGF-R antagonist is preferably administered by injection in an amount sufficient to inhibit formation of goblet cells in pulmonary airways. The degranulation of goblet cells that results in airway mucus production is thereby inhibited. Assays for screening candidate agents that inhibit goblet cell proliferation are also provided.
Preventing Airway Mucus Production By Administration Of Egf-R Antagonists
US Patent:
8071074, Dec 6, 2011
Filed:
Feb 27, 2008
Appl. No.:
12/038718
Inventors:
Jay A. Nadel - San Francisco CA, US
Kiyoshi Takeyama - Tokyo, JP
Kiyoshi Takeyama - Tokyo, JP
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 9/14, A01N 43/54
US Classification:
424 46, 424 45, 514266
Abstract:
Hypersecretion of mucus in the lungs is inhibited by the administration of an epidermal growth factor receptor (EGF-R) antagonist. The EGF-R antagonist may be in the form of a small organic molecule, an antibody, or portion of an antibody that binds to and blocks the EGF receptor. The EGF-R antagonist is preferably administered by injection in an amount sufficient to inhibit formation of goblet cells in pulmonary airways. The degranulation of goblet cells that results in airway mucus production is thereby inhibited. Assays for screening candidate agents that inhibit goblet cell proliferation are also provided.